FY2025 · period end Dec '25 · from the 10-K filed Feb 25, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $5.93B | $6.06B | $4.32B | $2.39B | $1.52B |
| Gross Profit | — | — | — | — | — |
| Operating Income | negative: -$0.46B | negative: -$0.29B | negative: -$0.23B | negative: -$0.11B | negative: -$0.37B |
| Net Income | negative: -$0.39B | negative: -$0.26B | negative: -$0.26B | negative: -$0.11B | negative: -$0.41B |
| EPS (Diluted) | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $1.27B | $1.73B | $1.74B | $1.70B | $1.59B |
| Total Liabilities | $1.14B | $1.26B | $1.08B | $0.66B | $0.49B |
| Stockholders' Equity | $0.13B | $0.47B | $0.66B | $1.04B | $1.09B |
| Cash & Equivalents | $0.17B | $0.19B | $0.11B | $0.47B | $1.04B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.11B | negative: -$0.06B | negative: -$0.16B | negative: -$0.13B | negative: -$0.15B |
| Capital Expenditures | $0.01B | $0.01B | $0.02B | $0.02B | $0.01B |
| Free Cash Flow | negative: -$0.12B | negative: -$0.07B | negative: -$0.17B | negative: -$0.15B | negative: -$0.15B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | negative: -0.1% | negative: -0.0% | negative: -0.1% | negative: -0.0% | negative: -0.2% |
| Net Margin | negative: -0.1% | negative: -0.0% | negative: -0.1% | negative: -0.0% | negative: -0.3% |
| Return on Equity | negative: -131.0% | negative: -46.0% | negative: -30.9% | negative: -10.0% | negative: -37.2% |
| Return on Assets | negative: -26.0% | negative: -15.0% | negative: -15.3% | negative: -6.5% | negative: -40.0% |
| Debt / Equity | 0.28× | 0.07× | 0.06× | 0.04× | 0.04× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001628280-26-053328 | Aug 5, 2026 | Aug 5, 2026 | Aug 5, 2026 20:07 UTC | EDGAR |
| 10-Q | 0001628280-26-053355 | Jun 30, 2026 | Aug 5, 2026 | Aug 5, 2026 20:11 UTC | EDGAR |
| 8-K | 0001628280-26-049080 | Jul 17, 2026 | Jul 22, 2026 | Jul 21, 2026 21:51 UTC | EDGAR |
| 8-K | 0001628280-26-040370 | Jun 2, 2026 | Jun 3, 2026 | Jun 3, 2026 20:31 UTC | EDGAR |
| 10-Q | 0001628280-26-031270 | Mar 31, 2026 | May 6, 2026 | May 6, 2026 20:11 UTC | EDGAR |
| 8-K | 0001628280-26-031254 | May 6, 2026 | May 6, 2026 | May 6, 2026 20:07 UTC | EDGAR |
| 8-K | 0001628280-26-027512 | Apr 24, 2026 | Apr 27, 2026 | Apr 27, 2026 20:18 UTC | EDGAR |
| 8-K | 0001628280-26-022074 | Mar 30, 2026 | Mar 30, 2026 | Mar 30, 2026 21:43 UTC | EDGAR |
Direct links to SEC EDGAR. AGL has additional filings available on the SEC site.
6 numbers agilon health, inc. later changed — same XBRL tag, both filings linked.
Operating Income (Loss)·Q1 2023
Major restatementwas$6.3M
Revised down in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2023
Major restatementwas$14.2M
Revised down in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2023
Major restatementwas-$30.3M
Revised up in a 10-Q.
Operating Income (Loss)·Q3 2023
Major restatementwas-$49M
Revised up in a 10-Q.
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2021
Major restatementwas$1.8B
Revised down in a 10-K. Any P/S built on the original was 20.5% too low.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2022
Major restatementwas-$105.7M
Revised up in a 10-K.
AGL is not the only one.
See every restatement we've found across the market — or get an alert the next time AGL revises a number.
Restatements are detected by comparing every vintage of a fact across all of agilon health, inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows AGL's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling agilon health, inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on AGL yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on AGL and publish the result to your public profile.
Ask about agilon health, inc.
Continue in Workspace — cited answers on AGL, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs